The Future of Prostate Cancer Biomarkers Is Multiplexed

July21_Technology_UrineBiomarkers

Combining urinary biomarkers improves clinical utility and provides a more robust evaluation

Combining urinary biomarkers allows a complete evaluation of prostate cancer cells while minimizing the risk of missing a foci of cancer or a unique mutation that drives clinical outcomes.

Here, we explore commercially available multiplex urine biomarkers for detecting prostate cancer.

Download the full infographic compliments of Clinical Lab Manager.

Download this free resource!

July21_Technology_UrineBiomarkers_infographic

 

ClinicalLM_logo

 

Clinical Lab Manager needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at anytime.
For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our privacy policy by clicking here.

Clinical-Logo
   
NOW PART OF THE LABX MEDIA GROUP:LABX MEDIA GROUP|LAB MANAGER


Clinical Lab Manager c/o LabX Media Group
1000 N West Street, Suite 1200, Wilmington, Delaware, USA, 19801 
Toll-Free: 888-781-0328 | (705) 528-6888
Email: privacy@clinicallabmanager.com 

 

© 2021 CLINICAL LAB MANAGER. ALL RIGHTS RESERVED.